Literature DB >> 19567250

Toxoplasma gondii: P30 peptides recognition pattern in human toxoplasmosis.

Nestor Cardona1, Alejandra de-la-Torre, Heber Siachoque, Manuel A Patarroyo, Jorge E Gomez-Marin.   

Abstract

In this study, human sera reactivity against nine peptides derived from the Toxoplasma gondii P30 protein was assessed by ELISA in patients with different clinical forms of toxoplasmosis. Same as has been reported in mice, sera from congenital, ocular and chronic asymptomatic toxoplasmosis patients recognized more strongly peptides from the protein's carboxy-terminus, being peptide 2017 (amino acids 301-320) the one most strongly recognized by sera from patients with ocular toxoplasmosis. Serum samples collected from 13 patients without ocular infection, 13 with inactive chorioretinal scars, 6 with active ocular infection and 10 seronegative individuals were then screened for anti-2017 IgG. Peptide 2017 was recognized by all patients' samples but not by sera from T. gondii-seronegative individuals. No statistically significant differences were found between the absorbance levels of groups with and without lesions or with active or inactive ocular lesions, as determined by ANOVA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19567250     DOI: 10.1016/j.exppara.2009.06.017

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  12 in total

Review 1.  Review on the identification and role of Toxoplasma gondii antigenic epitopes.

Authors:  Yanhua Wang; Guangxiang Wang; Jianping Cai; Hong Yin
Journal:  Parasitol Res       Date:  2015-11-19       Impact factor: 2.289

2.  Peptide microarray analysis of in silico-predicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans.

Authors:  Pavlo Maksimov; Johannes Zerweck; Aline Maksimov; Andrea Hotop; Uwe Gross; Uwe Pleyer; Katrin Spekker; Walter Däubener; Sandra Werdermann; Olaf Niederstrasser; Eckhardt Petri; Marc Mertens; Rainer G Ulrich; Franz J Conraths; Gereon Schares
Journal:  Clin Vaccine Immunol       Date:  2012-04-11

3.  Th1 and Th2 immune response to P30 and ROP18 peptides in human toxoplasmosis.

Authors:  Elizabeth Torres-Morales; Laura Taborda; Nestor Cardona; Alejandra De-la-Torre; Juan Carlos Sepulveda-Arias; Manuel Alfonso Patarroyo; Jorge Enrique Gomez-Marin
Journal:  Med Microbiol Immunol       Date:  2014-05-11       Impact factor: 3.402

Review 4.  Advances in serological, imaging techniques and molecular diagnosis of Toxoplasma gondii infection.

Authors:  Ali Rostami; Panagiotis Karanis; Shirzad Fallahi
Journal:  Infection       Date:  2018-01-12       Impact factor: 3.553

Review 5.  Toxoplasma gondii recombinant antigens as tools for serodiagnosis of human toxoplasmosis: current status of studies.

Authors:  Lucyna Holec-Gasior
Journal:  Clin Vaccine Immunol       Date:  2013-06-19

6.  Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and Chronic Toxoplasmosis.

Authors:  Jingjing Guo; Xiahui Sun; Huiquan Yin; Ting Wang; Yan Li; Chunxue Zhou; Huaiyu Zhou; Shenyi He; Hua Cong
Journal:  Front Cell Infect Microbiol       Date:  2018-05-23       Impact factor: 5.293

7.  Screening and identification of novel B cell epitopes of Toxoplasma gondii SAG1.

Authors:  Yanhua Wang; Guangxiang Wang; Delin Zhang; Hong Yin; Meng Wang
Journal:  Parasit Vectors       Date:  2013-04-30       Impact factor: 3.876

Review 8.  Research progress on surface antigen 1 (SAG1) of Toxoplasma gondii.

Authors:  Yanhua Wang; Hong Yin
Journal:  Parasit Vectors       Date:  2014-04-13       Impact factor: 3.876

9.  Analyzing and identifying novel B cell epitopes within Toxoplasma gondii GRA4.

Authors:  Yanhua Wang; Guangxiang Wang; Jiangtao Ou; Hong Yin; Delin Zhang
Journal:  Parasit Vectors       Date:  2014-10-10       Impact factor: 3.876

10.  Identifying Novel B Cell Epitopes within Toxoplasma gondii GRA6.

Authors:  Yanhua Wang; Guangxiang Wang; Jian Ping Cai
Journal:  Korean J Parasitol       Date:  2016-08-31       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.